RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of ...

Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...

Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.

Australians know bloody good horror. The country's been an unsung hero of the genre for an age, most notably rising on the ...

The data provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and ...

Oct. 17, 2024 The stock of Wave Life Sciences (NASDAQ:WVE), a global biotechnology company, has risen by 74% on Wednesday after a major development. The company has scored a landmark by delivering ...

A labor of love for debuting director Elizabeth Ai, the documentary charts an uprooted generation of young people and the ...

Recommended Reading Biotech startup Airna raises $60M for RNA editing medicines Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company ...